Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO). Leman R, Cherifi F, Leheurteur M, Theret P, et al. BMC Cancer 2025;25:1075.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leman R, Cherifi F, Leheurteur M, Theret P, et al. Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO). BMC Cancer 2025;25:1075.
PMID: 40597907